Question: 1101 

Evidence: No data concerning antiretroviral drug’s (ARV) primary resistance mutation rates in Chad are available. In the present report, we retrospectively investigated frozen dried blood spot (DBS) samples from HIV-1 Chadian patients who were naïve of ARV.

Rationale: The paper states that prior data for Chad were unavailable and that this study newly investigated ARV primary resistance in ARV-naïve Chadian patients, indicating the data are previously unpublished.

Answer: Yes


Question: 1102 

Evidence: HIV-1 protease and reverse transcriptase genes were successfully sequenced for 24 (60.0%) of the 40 patients displaying a viral load > 1000 copies/ml. All of our HIV-1 sequences were submitted to the Genbank and obtained an original accession number (Table 1).

Rationale: The text explicitly reports successful sequencing of HIV-1 genes and submission of sequences to GenBank, confirming that HIV sequences are reported.

Answer: Yes


Question: 1103 

Evidence: We retrospectively investigated frozen dried blood spot (DBS) samples from HIV-1 Chadian patients who were naïve of ARV. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy and obtained HIV-RNA nucleotide sequences were compared against referenced subtype B HBX-2 strain.

Rationale: The study design involved retrospective analysis of patient DBS samples with direct sequencing; there is no mention of laboratory in vitro passage experiments.

Answer: No


Question: 1104 

Evidence: Interpretation of sequencing results was performed according to the French National Agency for AIDS Research resistance algorithm. Protease sequences predicting phenotypic resistance to saquinavir and a combined resistance to nelfinavir, indinavir, and atazanavir were evidenced in 3 patients (12.5%).

Rationale: Resistance was inferred from genotypic algorithms and predictive interpretation; no in vitro phenotypic susceptibility assays were performed or reported.

Answer: No


Question: 2101 

Evidence: All of our HIV-1 sequences were submitted to the Genbank and obtained an original accession number (Table 1). Genbank reference entries are listed in Table 1.

Rationale: The paper states that sequences were submitted to GenBank and provides accession numbers in Table 1.

Answer: Yes


Question: 2102 

Evidence: 48 successive newly HIV-1 seropositive adult patients who were naïve of any ARV treatment ... were enrolled in the present investigation. All of our HIV-1 sequences were submitted to the Genbank and obtained an original accession number (Table 1).

Rationale: The sequences are from clinical, newly diagnosed ARV-naïve individuals rather than laboratory strains, and accession numbers are provided.

Answer: Yes


Question: 2103 

Evidence: All of our HIV-1 sequences were submitted to the Genbank and obtained an original accession number (Table 1). Genbank reference entries are listed in Table 1.

Rationale: The accession numbers are explicitly listed in Table 1; extracting them provides the requested list.

Answer: MW250353, MW250354, MW250355, MW250356, MW250357, MW250358, MW250359, MW250360, MW250361, MW250362, MW250363, MW250364, MW250365, MW250366, MW250367, MW250368, MW250369, MW250370, MW250371, MW250372, MW250373, MW250374, MW250375, MW250376, MW250377


Question: 2202 

Evidence: Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy. Protease and reverse transcriptase gene mutations were identified by HIV-RNA sequencing and are itemized in Table 1.

Rationale: Table 1 contains per-sample lists of protease and reverse transcriptase mutations, showing mutations for each individual sequenced isolate.

Answer: Yes


Question: 2301 

Evidence: 48 successive newly HIV-1 seropositive adult patients ... were enrolled. HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced.

Rationale: The study involved HIV-1-infected individuals and sequenced HIV-1 genes.

Answer: HIV-1


Question: 2302 

Evidence: The most prevalent HIV-1 subtype was circulating recombinant form (CRF) CRF11_CPX subtype and was identified in 7 of the 24 samples (29.2%). Other previously described HIV recombinant forms accounted for 8 out of the 24 samples (33.3%) (Table 1).

Rationale: Subtypes are listed in Table 1; combining the narrative and table contents yields the complete subtype list.

Answer: CRF11_CPX, B, G, CRF45_CPX, A1, CRF13_CPX, D, D.G (recombinant D/G), CRF02_AG


Question: 2303 

Evidence: HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy.

Rationale: The paper specifies the sequenced genes.

Answer: Protease and reverse transcriptase (pol gene regions)


Question: 2304 

Evidence: HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy.

Rationale: Protease and reverse transcriptase are components of HIV-1 pol; thus, the paper reports HIV pol sequences.

Answer: Yes


Question: 2401 

Evidence: 48 successive newly HIV-1 seropositive adult patients ... attending to the chronic diseases centre of the hospital "le Bon Samaritain" (N'Djamena, Chad) were enrolled. We retrospectively investigated frozen dried blood spot (DBS) samples from HIV-1 Chadian patients.

Rationale: The study population and sampling site were in N'Djamena, Chad.

Answer: Chad (N’Djamena)


Question: 2402 

Evidence: From August to November 2012, 48 successive newly HIV-1 seropositive adult patients ... were enrolled in the present investigation. Blood samples were collected before ARV.

Rationale: The sampling period is explicitly given.

Answer: 2012 (August–November)


Question: 2502 

Evidence: Each DBS sample was then stored at −80 °C until performing HIV-RNA viral load and genotyping assays in France according to previously described protocols [8, 9]. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy.

Rationale: The sequencing platform (e.g., Sanger) is not specified in the provided text; thus it cannot be determined.

Answer: NA


Question: 2503 

Evidence: Each DBS sample was then stored at −80 °C until performing HIV-RNA viral load and genotyping assays in France according to previously described protocols [8, 9]. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy.

Rationale: No explicit mention of an NGS technology is made; therefore, this cannot be determined from the text.

Answer: NA


Question: 2504 

Evidence: For each patient, blood samples were collected ... as dried blood spots (DBS) ... and genotyping assays were performed. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy.

Rationale: The text does not state whether molecular cloning of samples preceded sequencing.

Answer: NA


Question: 2505 

Evidence: Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy. Interpretation of sequencing results was performed according to the French National Agency for AIDS Research resistance algorithm.

Rationale: There is no mention of single-genome sequencing; thus it cannot be determined from the text.

Answer: NA


Question: 2506 

Evidence: Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy. No methods describing molecular cloning were provided.

Rationale: The study does not describe molecular cloning of viral genomes; this cannot be confirmed from the text.

Answer: NA


Question: 2601 

Evidence: For each patient, blood samples were collected ... as dried blood spots (DBS) ... An HIV-RNA viral load and genotyping assays were performed. Following RNA extraction from DBS ...

Rationale: Sequencing and viral load were performed from DBS, not from plasma; plasma sequencing is not reported.

Answer: No


Question: 2602 

Evidence: For each patient, blood samples were collected ... as dried blood spots (DBS). Our HIV genotyping results could be due to the combined presence of viral RNA and DNA in DBS ...

Rationale: PBMC sequencing is not reported; the source material was DBS rather than isolated PBMCs.

Answer: No


Question: 2603 

Evidence: For each patient, blood samples were collected ... as dried blood spots (DBS). Following RNA extraction from DBS ...

Rationale: Sequencing was performed from DBS, not plasma; hence the number of plasma virus sequences is zero.

Answer: 0


Question: 2604 

Evidence: For each patient, blood samples were collected ... as dried blood spots (DBS). Our HIV genotyping results could be due to the combined presence of viral RNA and DNA in DBS ...

Rationale: PBMC sequencing is not reported; therefore, the number of PBMC virus sequences is zero.

Answer: 0


Question: 2605 

Evidence: Following RNA extraction from DBS, median HIV-1 viral load was estimated to 4.72 log copies/ml ... for 40 ... with a detected viral load upper than 1000 copies per ml. HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced for only 24 ... of the 40 patients with a detectable viral load.

Rationale: Sequencing was performed on samples from patients with detectable viremia, indicating active HIV replication.

Answer: Yes


Question: 2606 

Evidence: HIV-RNA viral load and genotyping assays were performed. Our HIV genotyping results could be due to the combined presence of viral RNA and DNA in DBS and the detection of archived mutations ...

Rationale: Although genotyping targeted RNA, the authors note DBS can contain DNA, creating uncertainty about whether sequences reflect proviral DNA; this cannot be definitively determined.

Answer: NA


Question: 2701 

Evidence: 48 successive newly HIV-1 seropositive adult patients ... were enrolled. Median age 32 years [18–52].

Rationale: The cohort consisted of adults; no infants or children are reported.

Answer: No


Question: 2702 

Evidence: An oral informed consent for medical research investigations was obtained ... This study was approved by the local ethics committee (CHU-BS, Ndjamena, Chad, 2012).

Rationale: The study is an observational, ethics-approved investigation; there is no indication of a clinical trial.

Answer: No


Question: 2703 

Evidence: An oral informed consent for medical research investigations was obtained ... This study was approved by the local ethics committee (CHU-BS, Ndjamena, Chad, 2012).

Rationale: As the study is not a clinical trial, not all individuals were in a clinical trial.

Answer: No


Question: 3101 

Evidence: HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced for only 24 (60.0%) of the 40 patients with a detectable viral load (Table 1). Following RNA extraction from DBS ... 40 ... had a detected viral load upper than 1000 copies/ml.

Rationale: The number of individuals with successful HIV sequencing is 24.

Answer: 24


Question: 3102 

Evidence: HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced for only 24 (60.0%) of the 40 patients with a detectable viral load (Table 1). From a total of 48 enrolled patients, only 24 yielded sequences.

Rationale: Not all individuals underwent successful sequencing.

Answer: No


Question: 4101 

Evidence: 48 successive newly HIV-1 seropositive adult patients who were naïve of any ARV treatment ... were enrolled. All of these patients were newly HIV1-diagnosed and were sampled before initiation of ARV consisting of NRTI and NNRTI combination.

Rationale: The sequenced individuals were ART-naïve at sampling.

Answer: Yes


Question: 4102 

Evidence: 48 successive newly HIV-1 seropositive adult patients who were naïve of any ARV treatment ... were enrolled. All of these patients were ... sampled before initiation of ARV.

Rationale: There were no ART-experienced individuals sequenced.

Answer: No


Question: 4103 

Evidence: 48 successive newly HIV-1 seropositive adult patients who were naïve of any ARV treatment ... were enrolled. All of these patients were ... sampled before initiation of ARV.

Rationale: Only ART-naïve individuals were sequenced; no ART-experienced individuals are included.

Answer: No


Question: 4104 

Evidence: 48 successive newly HIV-1 seropositive adult patients who were naïve of any ARV treatment ... were enrolled. HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced for only 24 ... of the 40 patients with a detectable viral load.

Rationale: All sequenced samples (24) came from ART-naïve individuals.

Answer: 24


Question: 4105 

Evidence: 48 successive newly HIV-1 seropositive adult patients who were naïve of any ARV treatment ... were enrolled. All of these patients were ... sampled before initiation of ARV.

Rationale: The paper provides uniform pre-treatment ART history for all individuals (all ART-naïve).

Answer: Yes


Question: 4201 

Evidence: Seven (29.2%) displayed mutations conferring resistance against one or more classes of ARV. We evidenced high levels of primary ARV resistance mutations in Chad.

Rationale: Among ART-naïve individuals, the prevalence of transmitted (primary) resistance mutations was quantified.

Answer: Yes


Question: 4202 

Evidence: Seven (29.2%) displayed mutations conferring resistance against one or more classes of ARV. We evidenced high levels of primary ARV resistance mutations in Chad.

Rationale: Primary (pretreatment) resistance prevalence is directly reported for the ART-naïve cohort.

Answer: Yes


Question: 4301 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). 

Rationale: The treatment classes administered were nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.

Answer: NRTIs and NNRTIs


Question: 4302 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). Dolutegravir-containing regimen is now recommended by the WHO, but to date, this ARV drug is not yet in full free access for the population of Chad.

Rationale: No individuals received integrase inhibitors; integrase inhibitor access (dolutegravir) was not yet broadly available.

Answer: No


Question: 4303 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). 

Rationale: The reported treatment regimens did not include protease inhibitors for these individuals.

Answer: No


Question: 4304 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). 

Rationale: Although all regimens were NRTI+NNRTI, the specific drugs varied (efavirenz or nevirapine), so they did not all receive the exact same ART.

Answer: No


Question: 4305 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). Dolutegravir-containing regimen ... is not yet in full free access for the population of Chad.

Rationale: No integrase inhibitors were used, so participants were INSTI-naïve.

Answer: Yes


Question: 4403 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). Among these 24 patients, 4 died (16.6%), and 14 (58.3%) were lost to follow-up.

Rationale: The paper does not provide detailed longitudinal regimen-switch data; it only states initial regimens and high attrition, so the number receiving more than one regimen cannot be determined.

Answer: NA


Question: 4404 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). Among these 24 patients, 4 died ... and 14 ... were lost to follow-up.

Rationale: There is no information about receipt of more than two regimens.

Answer: NA


Question: 4405 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). Among these 24 patients, 4 died ... and 14 ... were lost to follow-up.

Rationale: The paper does not report the number of regimens per individual beyond initial treatment.

Answer: NA


Question: 4406 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). 

Rationale: Although an initial regimen is reported, the paper does not confirm whether all individuals received only one regimen throughout follow-up.

Answer: NA


Question: 4501 

Evidence: Dolutegravir-containing regimen is now recommended by the WHO, but to date, this ARV drug is not yet in full free access for the population of Chad. All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine).

Rationale: The study reports only NRTI+NNRTI regimens, and notes dolutegravir was not yet broadly accessible.

Answer: 0


Question: 4502 

Evidence: All patients were treated by NRTI plus first-generation NNRTI (such as efavirenz or nevirapine). 

Rationale: There is no report of darunavir use; only NRTI+NNRTI regimens are described.

Answer: 0


Question: 5101 

Evidence: Seven (29.2%) of the 24 successfully sequenced DBS samples exhibited referenced nucleotide mutations conferring HIV-1-resistance against at least one antiretroviral drug. HIV-1 protease and reverse transcriptase genes were successfully amplified and sequenced for only 24 ... patients.

Rationale: The paper gives the exact count of individuals with at least one resistance mutation among those sequenced.

Answer: 7


Question: 5102 

Evidence: Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy. 

Rationale: The integrase gene was not sequenced; therefore, no INSTI-resistance mutations were identified.

Answer: 0


Question: 5103 

Evidence: One K65E ... was also detected in two distinct individuals conferring resistance to tenofovir and rilpivirine, respectively. In Table 1, patient 2 shows K65E with possible drug resistance listed as TDF.

Rationale: K65E is a tenofovir resistance-associated mutation and was observed in one individual.

Answer: 1


Question: 5104 

Evidence: Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy. The study did not sequence the integrase gene.

Rationale: Because integrase was not sequenced, no INSTI-resistance mutations were reported.

Answer: NA


Question: 6101 

Evidence: Interpretation of sequencing results was performed according to the French National Agency for AIDS Research resistance algorithm. Protease sequences predicting phenotypic resistance ... were evidenced in 3 patients (12.5%).

Rationale: The study inferred resistance from genotypes and did not describe any phenotypic susceptibility testing methods.

Answer: NA


Question: 6102 

Evidence: Interpretation of sequencing results was performed according to ... resistance algorithm. No IC50 or IC90 values are presented in the results.

Rationale: The paper does not report IC measurements.

Answer: No


Question: 6103 

Evidence: Protease sequences predicting phenotypic resistance ... were evidenced in 3 patients (12.5%). The study relies on algorithmic interpretation rather than reporting fold-change IC50 values.

Rationale: No IC50 fold-change data are presented.

Answer: No


Question: 6104 

Evidence: Interpretation of sequencing results was performed according to ... resistance algorithm. No phenotypic assay methodology is described.

Rationale: The paper does not report a phenotypic susceptibility assay.

Answer: NA


Question: 6105 

Evidence: The results section details mutations and predicted resistance without mentioning replication capacity. There is no report of replication capacity measurements.

Rationale: Replication capacity data are absent.

Answer: No


Question: 6106 

Evidence: Protease sequences predicting phenotypic resistance ... were evidenced in 3 patients (12.5%). No phenotypic susceptibility testing against specific drugs is described.

Rationale: As no phenotypic assays were performed, no drugs were tested phenotypically in this study.

Answer: NA


Question: 7101 

Evidence: We retrospectively investigated frozen dried blood spot (DBS) samples from HIV-1 Chadian patients who were naïve of ARV. Protease and reverse transcriptase gene regions were fully covered by our sequencing strategy.

Rationale: The isolates are patient-derived sequences; no site-directed mutagenesis was performed.

Answer: No


Question: 7102 

Evidence: We retrospectively investigated frozen dried blood spot (DBS) samples from HIV-1 Chadian patients who were naïve of ARV. Following RNA extraction from DBS ... sequences were obtained.

Rationale: There were no in vitro passage experiments; sequences came directly from clinical samples.

Answer: No